Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration
- PMID: 21149649
- DOI: 10.1200/JCO.2010.32.6751
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration
Comment on
-
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.J Clin Oncol. 2010 Sep 20;28(27):4207-13. doi: 10.1200/JCO.2009.26.8896. Epub 2010 Aug 16. J Clin Oncol. 2010. PMID: 20713865 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
